50
Participants
Start Date
May 31, 2025
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2026
Ixekizumab
Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER